62IN - Reclassifying lung cancer and molecular diagnostic

Date 29 September 2014
Event ESMO 2014
Session The evolving role of systemic treatment in advanced NSCLC
Topics Non-Small-Cell Lung Cancer, Metastatic
Pathology/Molecular Biology
Presenter Ramaswamy Govindan
Citation Annals of Oncology (2014) 25 (suppl_4): iv23-iv23. 10.1093/annonc/mdu304
Authors R. Govindan, S. Devarakonda
  • Division Of Oncology, Washington University School of Medicine, 63110 - St. Louis/US




Lung cancer has traditionally been classified based on tumor histology. However, with the advent of targeted therapies, the utility of this classification scheme in guiding clinical decisions is limited. Several studies have consistently highlighted the molecular heterogeneity underlying lung cancers. Using gene-expression data, investigators have classified adenocarcinomas (LUAD) into “bronchoid”, “squamoid”, and “magnoid” subtypes, and squamous cell cancers (SQCC) into “primitive”, “classical”, “secretory”, and “basal” subtypes. Further, next-generation sequencing data from the Cancer Genome Atlas (TCGA), have confirmed the reproducibility of these subtypes, and have also facilitated a study of the mutational, gene copy-number, and epigenetic features underlying these tumors. Similarly, it has also shown large cell lung cancer can be subdivided based on the molecular features. It is conceivable that classifying cancers based on common transcriptional features and biological themes identify may identify subgroups of patients at risk for recurrence following surgical resection.


R. Govindan: Consultant for: Boehringer Ingelheim, GlaxoSmithKline, Pfizer, Merck, Bayer, Covidien, Bristol Myers-Squibb, Genentech (Roche), Mallinckrodt Honoraria received.

All other authors have declared no conflicts of interest.